POM (Pomdoctor) Research & Development: $1.82 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

POM Pomdoctor Ltd POM
20 GF Score
Price $1.02
! 7 Warning Signs
View Full Analysis

What is Pomdoctor Research & Development?

Pomdoctor POM +4.66% 20 Research & Development is $1.82 Mil as of Dec. 2025. GuruFocus rates POM with a GF Score™ of 20/100. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pomdoctor's Research & Development for the six months ended in Dec. 2025 was $1.62 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $1.82 Mil.

Pomdoctor  (NAS:POM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pomdoctor Research & Development Related Terms

Pomdoctor Research & Development Historical Data

* Premium members only.

The historical data trend for Pomdoctor's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pomdoctor Research & Development Chart

Pomdoctor Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.67 0.52 0.47 0.41 1.83

Pomdoctor Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.21 0.21 0.21 0.21 1.62
POM
20GF Score
Pomdoctor Ltd POM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pomdoctor Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1.82 Mil mean?
Pomdoctor (POM) has a Research & Development of $1.82 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Pomdoctor and its competitors.
Is Pomdoctor's Research & Development too high?
Pomdoctor's current Research & Development is $1.82 Mil. Overall, Pomdoctor has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pomdoctor's Research & Development compare to BLMH and HEWA?
Pomdoctor's Research & Development of $1.82 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pomdoctor and its competitors. Pomdoctor's current Research & Development is $1.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pomdoctor stock overvalued right now?
Pomdoctor (POM) has a current Research & Development of $1.82 Mil. The current Research & Development is $1.82 Mil. Pomdoctor's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pomdoctor (POM), the current Research & Development is $1.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pomdoctor Business Description

Address No.19-23 Hejing Road, Dongsha Street, Yongxu Industrial Park, Liwan District, Guangzhou, CHN, 510000
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.
20GF Score

Get the complete analysis for POM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.02
Price